 |
|
|
|
 |
|
|
 Contact |  Print version |  PDF version |  Send article |  RSS-Feed
Medgenics consolidates corporate and R&D operations into new office facility20 Mar 2008 -
Medgenics has completed its move to a new facility on the Teradion Business Park in Misgav, Israel. The new facility brings together Medgenics' corporate operations with larger R&D laboratories on one site.
At the same time, the Company has more than doubled its scientific and engineering staff from four at Admission to ten now, in accordance with its plan and preparation for the Phase I/II clinical trial for EPODURE: its lead product in development to deliver a sustained therapeutic dose of erythropoietin (EPO) for the long-term treatment of anaemia. Subject to regulatory approval, EPODURE is on schedule to begin Phase I/II clinical trials in mid 2008 and preliminary data are anticipated from these trials within 3-5 months of trial commencement.
Additional information
Medgenics, Inc.
Vienna, VA, United States of America
Company
News
|
|
|
|
|
|
Top
